These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 6887354)

  • 41. Prognosis of renal adenocarcinoma in a central hospital.
    Arvola I; Lilius HG
    Ann Chir Gynaecol Fenn; 1972; 61(4):223-6. PubMed ID: 4640308
    [No Abstract]   [Full Text] [Related]  

  • 42. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
    Belldegrun A; Shvarts O; Figlin RA
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transcatheter embolization of advanced renal cell carcinoma with radioactive seeds.
    Lang EK; deKernion JB
    J Urol; 1981 Nov; 126(5):581-6. PubMed ID: 6170767
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Distant metastasis of renal adenocarcinoma in nephrectomized cases.
    Saitoh H; Nakayama M; Nakamura K; Satoh T
    J Urol; 1982 Jun; 127(6):1092-5. PubMed ID: 7087014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor.
    Figlin RA; Pierce WC; Kaboo R; Tso CL; Moldawer N; Gitlitz B; deKernion J; Belldegrun A
    J Urol; 1997 Sep; 158(3 Pt 1):740-5. PubMed ID: 9258071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bilateral renal cell carcinoma: influence of synchronous and asynchronous occurrence on patient survival.
    Zincke H; Swanson SK
    J Urol; 1982 Nov; 128(5):913-5. PubMed ID: 7176050
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
    Jeon SH; Chang SG; Kim JI
    Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The value of transvascular embolization in the treatment of renal carcinoma.
    Christensen K; Dyreborg U; Andersen JF; Nissen HM
    J Urol; 1985 Feb; 133(2):191-3. PubMed ID: 3968730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic implications of vena caval extension of renal cell carcinoma.
    Cherrie RJ; Goldman DG; Lindner A; deKernion JB
    J Urol; 1982 Nov; 128(5):910-2. PubMed ID: 7176049
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term results following partial nephrectomy for localized renal adenocarcinoma.
    Topley M; Novick AC; Montie JE
    J Urol; 1984 Jun; 131(6):1050-2. PubMed ID: 6726899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The treatment of renal cell carcinoma with human leukocyte alpha-interferon.
    deKernion JB; Sarna G; Figlin R; Lindner A; Smith RB
    J Urol; 1983 Dec; 130(6):1063-6. PubMed ID: 6644883
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medroxyprogesterone in metastatic renal cell carcinoma.
    Rao MK; Soloway MS
    South Med J; 1980 Feb; 73(2):247-8. PubMed ID: 7355330
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current treatment of metastatic renal cell carcinoma with xenogeneic immune ribonucleic acid.
    Richie JP; Steele GD; Wilson RE; Ervin T; Wang BS; Mannick JA
    J Urol; 1984 Feb; 131(2):236-8. PubMed ID: 6199519
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer.
    Russo P; Synder M; Vickers A; Kondagunta V; Motzer R
    ScientificWorldJournal; 2007 Feb; 7():768-78. PubMed ID: 17619759
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Embolization of renal carcinoma.
    Wallace S; Chuang VP; Swanson D; Bracken B; Hersh EM; Ayala A; Johnson D
    Radiology; 1981 Mar; 138(3):563-70. PubMed ID: 7465831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surgical treatment of metastatic renal cell carcinoma.
    Tobisu K; Kakizoe T; Takai K; Tanaka Y; Mizutani T
    Jpn J Clin Oncol; 1990 Sep; 20(3):263-7. PubMed ID: 2255101
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Aggressive versus conservative management of stage IV renal cell carcinoma.
    Klugo RC; Detmers M; Stiles RE; Talley RW; Cerny JC
    J Urol; 1977 Aug; 118(2):244-6. PubMed ID: 894800
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preoperative Neutrophil to Lymphocyte Ratio as a Prognostic Factor in Patients with Non-metastatic Renal Cell Carcinoma.
    Wen RM; Zhang YJ; Ma S; Xu YL; Chen YS; Li HL; Bai J; Zheng JN
    Asian Pac J Cancer Prev; 2015; 16(9):3703-8. PubMed ID: 25987025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The treatment of renal cell carcinoma with solitary metastasis.
    O'dea MJ; Zincke H; Utz DC; Bernatz PE
    J Urol; 1978 Nov; 120(5):540-2. PubMed ID: 712892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.